AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31412955
Drug: NI-03 (camostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NI-03 (camostat mesilate) administered three times daily at doses of 100, 200, or 300 mg for 28 days
Trial: 22453316
Drug: Docusate sodium
RxNorm normalized name: Docusate Sodium
DrugBank: Docusate (DB11089)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docusate sodium plus Miralax, fiber wafers, and bisacodyl suppositories
Trial: 10613592
Drug: EPO plus
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO plus G-CSF combination after PBPCT
Trial: 386390
Drug: Amitriptyline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (150 mg/d)
Trial: 8600497
Drug: Acetaminophen (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (2,000 mg/d)
Trial: 2007941
Drug: Ceftriaxone, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone, 50 mg/kg per day for 5 days
Trial: 2007941
Drug: Ampicillin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, 100 mg/kg per day for 5 days
Trial: 7102737
Drug: No introduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No introduction with oral presentation
Trial: 28831548
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 50 mg/day oral, increased to 2-3 mg/kg/day with oral prednisolone as adjunctive therapy
Trial: 28831548
Drug: Rituximab (RIT)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RIT) 1 g intravenous, repeated 2 weeks later and then every 6 months
Trial: 21303732
Drug: OROS-methylphenidate (OROS-MPH),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-methylphenidate (OROS-MPH), mean daily dose 84.6±31.6 mg (1.04±0.29 mg/kg)
Trial: 21303732
Drug: Placebo, mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, mean daily dose 100.5±21.9 mg (1.20±0.11 mg/kg)
Trial: 19530576
Drug: Standard rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rescue drugs (Tramadol)
Trial: 19530576
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg intramuscular every 12 hours for 2 doses
Trial: 12901874
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (250 mg/day)
Trial: 1680327
Drug: Salbutamol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.1 mg) in customary metered-dose inhaler
Trial: 1680327
Drug: Pirbuterol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirbuterol (0.2 mg) in Autohaler
Trial: 7040820
Drug: Chemoimmunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy with DTIC plus intradermal BCG
Trial: 7040820
Drug: Methyl‐CCNU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl‐CCNU plus intradermal BCG
Trial: 29094315
Drug: Umeclidinium/Vilanterol (UMEC/VI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg once daily
Trial: 29094315
Drug: Tiotropium/Olodaterol (TIO/OLO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/Olodaterol (TIO/OLO) 5/5 µg once daily
Trial: 26433562
Drug: Reduced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced standard treatment combined with the computer‐based therapeutic education system (TES)
Trial: 15598196
Drug: Standard methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methadone maintenance treatment
Trial: 23713301
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (clomifene and HCG)
Trial: 19917523
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) and Vitamin C and E (VCE) supplementation
Trial: 19917523
Drug: No HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No HRT treatment (Control)
Trial: 25735993
Drug: MDMA (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.0 mg/kg)
Trial: 15975736
Drug: mCPP (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mCPP (0.75 mg/kg)
Trial: 15285969
Drug: Seeking Safety
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seeking Safety therapy
Trial: 8204997
Drug: Paroxetine 30
RxNorm normalized name: PARoxetine 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 30 mg per day
Trial: 18721703
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution (control)
Trial: 30707225
Drug: Repeated antenatal
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated antenatal betamethasone treatment
Trial: 22469291
Drug: Up front
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up front surgery of the breast tumor followed by systemic therapy
Trial: 22469291
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy followed by delayed local treatment of the breast tumor if clinically indicated
Trial: 20413364
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg plus fenofibric acid 135 mg daily for 18 months
Trial: 17507311
Drug: Enediyne compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enediyne compounds
Trial: 15610940
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) isradipine 30 mg
Trial: 15008726
Drug: ProstaLund Feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProstaLund Feedback Treatment (PLFT)
Trial: 10202826
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination regimen (NVP + ddl + ZDV)
Trial: 20083352
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection
Trial: 26983925
Drug: Lidocaine cream
RxNorm normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine cream
Trial: 3243094
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 1.5 g and 1.2 g
Trial: 3243094
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 2 g (single dose)
Trial: 3243094
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 2 g for 10 days
Trial: 3243094
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 1 g
Trial: 3243094
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 2 g
Trial: 27330698
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg bid for 3 weeks
Trial: 25907848
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - wait-list IRD (no treatment)
Trial: 25907848
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - typically developing readers (no treatment)
Trial: 10806602
Drug: Sibrafiban with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban with ASA and heparin
Trial: 30836981
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of renin-angiotensin system inhibitors (RASi) 48 hours before surgery
Trial: 29369904
Drug: PRP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP treatment (1.0 × 10 platelets/cm sprayed on wound)
Trial: 17608755
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg/day) for 36 months
Trial: 7978420
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg droperidol (Group 1, n = 10)
Trial: 7978420
Drug: 0.175 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.175 mg/kg droperidol (Group 2, n = 10)
Trial: 1708060
Drug: Cilazapril 2.5
RxNorm normalized name: cilazapril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2.5 mg
Trial: 668773
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg
Trial: 30580672
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy and treadmill training
Trial: 26095747
Drug: Ropivacaine 0.197%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.197% with adjunct dexmedetomidine 0.3 μg·kg(‐1) (Group LAD)
Trial: 19446149
Drug: Eltrombopag 50
RxNorm normalized name: eltrombopag 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 50 mg with high-fat, high-calcium breakfast
Trial: 19446149
Drug: Eltrombopag 75
RxNorm normalized name: eltrombopag 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 75 mg with low-fat, low-calcium meal
Trial: 19446149
Drug: Eltrombopag 75
RxNorm normalized name: eltrombopag 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 75 mg with high-fat, low-calcium meal
Trial: 19446149
Drug: Eltrombopag 75
RxNorm normalized name: eltrombopag 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 75 mg with antacid containing aluminum hydroxide and magnesium carbonate
Trial: 15247109
Drug: epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epidural ketamine 1 mg kg(‐1) in 10 ml plus i.m. normal saline
Trial: 15247109
Drug: epidural normal
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epidural normal saline 10 ml plus i.m. normal saline 10 ml
Trial: 30810382
Drug: Weekly 50
RxNorm normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly 50 mg of transdermal testosterone plus daily oral 1 mg estradiol valerate for 8 weeks
Trial: 9248985
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg)
Trial: 27573564
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg bid)
Trial: 15237706
Drug: Insulin gene
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin gene pattern risk scores (summed risk score from two single nucleotide polymorphisms: -23 Hph I; +1127 Pst I)
Trial: 11904741
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of parenteral iron
Trial: 11904741
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of parenteral iron
Trial: 2744068
Drug: Witepsol H12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Witepsol H12 suppositories containing 75 mg, 100 mg, and 150 mg of meptazinol
Trial: 2744068
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral tablet of meptazinol
Trial: 76752
Drug: Acid-phosphatase reaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-phosphatase reaction in null-A.L.L.
Trial: 22906516
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg/day, n = 34)
Trial: 22906516
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg/day) in normal DβH level genotype
Trial: 22906516
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg/day) in low DβH level genotype
Trial: 21266648
Drug: Home use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home use of a smartphone recommending insulin doses with quarterly visits (G2)
Trial: 19856688
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.25% bupivacaine (2 mL/h) plus intravenous analgesics
Trial: 8721527
Drug: Acute allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute allergen challenge (increasing doses every 15 min until symptoms occurred) in 9 patients.
Trial: 8721527
Drug: Repeated low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Repeated low-dose allergen exposure (one small dose daily for 7 days) in 10 patients.
Trial: 28132705
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment
Trial: 9727214
Drug: Assertive Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive Community Treatment (ACT) model
Trial: 15953302
Drug: Relaxation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation treatment
Trial: 8360369
Drug: Relaxation+efficacy-enhancement treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation+efficacy-enhancement treatment
Trial: 2242740
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation
Trial: 3963319
Drug: Oral premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral premedication
Trial: 16030279
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg IV)
Trial: 14622076
Drug: Experiential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential treatment for depression (16-20 sessions)
Trial: 8964866
Drug: rhGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH therapy (4 IU/m2.day, sc)
Trial: 1804652
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) administration of midazolam 0.2 mg.kg‐1
Trial: 1804652
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of midazolam 0.2 mg.kg‐1
Trial: 1763589
Drug: Buprenorphine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.15 mg)
Trial: 6402201
Drug: Meptazinol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (50 mg)
Trial: 8368552
Drug: Morphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (5 mg)
Trial: 6402201
Drug: Pethidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (50 mg)
Trial: 6402201
Drug: Intramuscular analgesic
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular analgesic system
Trial: 6402201
Drug: Intravenous on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous on demand systems
Trial: 12215236
Drug: Nicotine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (7 mg/24 h)
Trial: 24777591
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of NOMAC/E2 (2.5/1.5 mg)
Trial: 16968566
Drug: Eszopiclone 2
RxNorm normalized name: eszopiclone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 2 mg
Trial: 16477959
Drug: Eszopiclone 1
RxNorm normalized name: eszopiclone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 1 mg
Trial: 10924966
Drug: Hyperfractionation at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionation at 1.2 Gy/fraction, twice daily, 5 days/week to 81.6 Gy/68 fractions/7 weeks
Trial: 10924966
Drug: Accelerated fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated fractionation with concomitant boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 Gy/fraction/day to a boost field for the last 12 treatment days to 72 Gy/42 fractions/6 weeks
Trial: 30501824
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroid cover (group 2)
Trial: 26581718
Drug: DEX implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX implant 0.7 mg
Trial: 26581718
Drug: DEX implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX implant 0.35 mg
Trial: 23072538
Drug: Sugar solution
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar solution (control)
Trial: 12421773
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose corticosteroid infusion for 48 hours after head injury
Trial: 12198662
Drug: Sandostatin LAR
RxNorm normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sandostatin LAR 30 mg injection once every 4 weeks for 6 doses
Trial: 9518395
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (3 or more insulin injections daily or continuous subcutaneous infusion of insulin, guided by 4 or more glucose tests per day)
Trial: 9518395
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (1 or 2 insulin injections daily)
Trial: 7536209
Drug: rhIGF‐I (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I (120 micrograms/kg, sc, daily)
Trial: 214218
Drug: oral 5‐Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral 5‐Fluorouracil (5FU)
Trial: 7043345
Drug: Ticarcillin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin (6 g intravenously immediately after delivery, with a second 3-g dose 6 to 8 hours after delivery for some patients)
Trial: 24626789
Drug: Pharmacotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy and family‐focused treatment (21 sessions over 9 months)
Trial: 24626789
Drug: Pharmacotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy and enhanced care (three weekly sessions of family psychoeducation)
Trial: 10531630
Drug: Methadone formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone formulation 2
Trial: 10531630
Drug: Methadone formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone formulation 3
Trial: 10531630
Drug: Methadone formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone formulations (all)
Trial: 24463982
Drug: Placebo Oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Appliance (POA)
Trial: 10740301
Drug: Intravenous ethamsylate
RxNorm normalized name: ethamsylate
DrugBank: Etamsylate (DB13483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ethamsylate (12.5 mg/kg) six hourly for four days
Trial: 7039401
Drug: FPL 57787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPL 57787 18 mg x 4
Trial: 20136418
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of 2.5 mg (0.1 ml) bevacizumab
Trial: 10340796
Drug: Methylprednisolone pulse
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone pulse treatment
Trial: 8636344
Drug: GH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH administration (0.1 IU/kg x day)
Trial: 8636344
Drug: T3 administration
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 administration (40 microg on even dates, 20 microg on uneven dates)
Trial: 1767711
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of H2 receptor antagonists or sucralfate (4 gr/day)
Trial: 1767711
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg, single dose
Trial: 53555
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg orally
Trial: 17083009
Drug: MenPS (meningococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenPS (meningococcal AC plain polysaccharide vaccine)